HDtDCS in Logopenic Variant PPA: Effects on Language and Neural Mechanisms



Status:Not yet recruiting
Conditions:Neurology, Neurology
Therapuetic Areas:Neurology
Healthy:No
Age Range:45 - Any
Updated:1/18/2019
Start Date:June 2019
End Date:May 2021
Contact:Barbara Blaney
Email:bblaney@mcw.edu
Phone:414-955-0609

Use our guide to learn which trials are right for you!

High-Definition Transcranial Direct Current Stimulation (HD-tDCS) in Logopenic Variant Primary Progressive Aphasia (lvPPA): Effects on Language and Neural Mechanisms

This study aims to evaluate the effectiveness of a therapy called High-Definition
Transcranial Direct Current Stimulation (HD-tDCS) for the treatment of the language deficits
experienced by people with a type of Primary Progressive Aphasia. This study uses a
combination of brain imaging, language assessment, language training sessions, and HD-tDCS
therapy as well as placebo therapy sessions.

The logopenic variant of Primary Progressive Aphasia (lvPPA) is an untreatable
neurodegenerative disorder that is often referred to as the 'language form' of Alzheimer's
Disease (AD). Transcranial Direct Current Stimulation (tDCS) has emerged as a safe and
potentially effective tool that appears to enhance language production when delivered during
language training. This technology provides a critical opportunity to conduct disease
intervention.

In this study, the investigators will test the hypothesis that High-Definition tDCS (HD-tDCS)
will improve performance on language tasks by increasing functional connectivity and by
regulating abnormal neuronal oscillatory patterns. The rationale for this project is that a
determination of the therapeutic efficacy and the associated neural mechanisms of HD-tDCS in
lvPPA is likely to offer a scientific framework whereby new stimulation parameters,
conditions, and target sites can be deciphered.

This study will test the hypothesis that HD-tDCS will improve performance on language tasks
by increasing functional connectivity and by regulating abnormal neuronal oscillatory
patterns. The language performance and functional connectivity changes will be determined in
a randomized, double-blind, sham-controlled crossover manner, in which a stimulation of up to
2mA in the targeted cortical tissue or sham is administered to 20 lvPPA subjects age 45 years
and older. The order of treatments is counterbalanced in a within-subject crossover design.
In brief, study participants will receive sham during one treatment period and stimulation
during the other treatment period.

Inclusion Criteria:

- Diagnosed with language variant Primary Progressive Aphasia (lvPPA) subtype, defined
as either clinical lvPPA or imaging-supported lvPPA in accordance with the most recent
diagnostic criteria (Mesulam., 2001; Gorno-Tempini et al., 2011).

- Fluent in English.

- 45 years of age or older.

- Structural brain MRI performed within 2 years prior to enrollment.

Exclusion Criteria:

- Severe cognitive, auditory or visual impairments that would preclude cognitive
testing.

- Presence of major untreated or unstable psychiatric disease.

- A chronic medical condition that is not treated or is unstable.

- The presence of cardiac stimulators or pacemakers.

- Any metal implants in the skull

- Contraindications to MRI

- History of seizures

- History of dyslexia or other developmental learning disabilities.
We found this trial at
1
site
8701 W Watertown Plank Rd
Milwaukee, Wisconsin
(414) 955-8296
Principal Investigator: Elias Granadillo, MD
Phone: 414-955-0609
Medical College of Wisconsin The Medical College (MCW) of Wisconsin is a major national research...
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials